# A Systematic Review of Graft‐Related Complications and Recurrence Following Minimally Invasive Sacrocolpopexy With Xenografts and Allografts

## TL;DR

This review compares complications and recurrence rates of biological grafts used in minimally invasive sacrocolpopexy, finding higher recurrence than synthetic grafts.

## Contribution

The study provides a systematic review and meta-analysis of biological graft outcomes in sacrocolpopexy, highlighting recurrence and graft-related complications.

## Key findings

- Pooled recurrence rate was 25.6% with biological grafts in minimally invasive sacrocolpopexy.
- Graft exposure occurred in 0.8% of cases, with no exposure reported for acellular dermal matrix (ADM).
- Tutoplast cadaveric fascia lata showed the highest recurrence (52.6%) and exposure (5.3%).

## Abstract

Biological grafts are proposed as an alternative to synthetic grafts in sacrocolpopexy (SC) to reduce complications such as graft exposure and immunologic reactions. However, concerns remain long‐term durability. This systematic review and meta‐analysis assess recurrence rates and graft‐related complications (GRC) in minimally invasive sacrocolpopexy (MISC) using biological grafts.

To evaluate the recurrence and GRC following MISC with biological grafts and to compare outcomes across different materials.

PubMed, Embase and Cochrane databases were searched up to August 2024.

Studies with ≥ 10 patients undergoing MISC with biological grafts, reporting recurrence or GRC with ≥ 6 months follow‐up, were included.

Two independent reviewers assessed study quality using the Newcastle‐Ottawa Scale (NOS). A random‐effects meta‐analysis estimated pooled recurrence and GRC with 95% confidence intervals (CI).

Five studies (353 patients) met inclusion criteria. Recurrence rates ranged from 2.4% to 52.6% (pooled: 25.6% [95% CI: 8.1%–48.2%]). Graft exposure occurred in 0.8% (95% CI: 0.0%–4.2%). ADM had the lowest recurrence (2.4%) with no reported exposures, whereas Tutoplast cadaveric fascia lata showed the highest recurrence (52.6%) and exposure (5.3%). The pooled reoperation rate for recurrence was 16.8% (95% CI: 0.0%–51.7%).

This systematic review identified a higher recurrence rate with biological grafts in MISC than typically reported for synthetic grafts in other literature, while exposure rates appeared to be comparable. Given study heterogeneity, further research is required to determine the optimal graft choice balancing durability and complication risk.